MedPath

Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths

Not Applicable
Recruiting
Conditions
Oncologic Complications and Emergencies
Interventions
Device: Introcan Safety IV Catheter
Registration Number
NCT06217783
Lead Sponsor
M.D. Anderson Cancer Center
Brief Summary

To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.

Detailed Description

Primary Objectives:

- The rate of catheter failure, defined as removal of the catheter for any reason other than "Care Complete" (i.e. a composite of removal due to "infiltration," "leaking," "catheter damage," "occlusion"), by day 10.

Secondary Objectives:

1. Time from catheter placement to removal (i.e. survival or dwell time).

2. Per catheter length rate of failure analysis

3. Rate of repeat catheterization

4. Rate of infection

5. Rate of thrombosis

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria
  1. Age > 18 years old.
  2. Provision of signed and dated informed consent form.
  3. Predetermined to have difficult IV access necessitating USIV placement
  4. Expected admission to hospital with anticipated stay > 48 hours (per discussion with treating physician).
Exclusion Criteria
  1. Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician).
  2. Inability to give informed consent.
  3. Pregnant women.
  4. Non-English speaking participants.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group AIntrocan Safety IV CatheterParticipants will receive a catheter that is up to 1.75 inches long based on what the nurse thinks is best for you.
Group BIntrocan Safety IV CatheterParticipants will receive a catheter that is either 1.75 or 2.5 inches long based on what the nurse thinks is best for you.
Primary Outcome Measures
NameTimeMethod
Safety and adverse events (AEs)Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath